Generic Drug News and Research

RSS

Generic Drugs are official nonbrand names by which medicines are known. Generic names usually refer to the chemical name of the drug.

First generic version of Xeloda gets FDA approval for breast and colorectal cancers

The U.S. Food and Drug Administration today approved the first generic version of Xeloda (capecitabine), an oral chemotherapy pill used to treat cancer of the colon or rectum (colorectal cancer) that has spread to other parts of the body (metastatic), and metastatic breast cancer.

17 Sep 2013

Walgreens’ August sales increased by 5.6% to $6.17 billion

Walgreens had August sales of $6.17 billion, an increase of 5.6 percent from $5.84 billion for the same month in fiscal 2012.

5 Sep 2013

Neurodyn acquires all assets related to new drug candidate Memogain from Galantos Pharma

Neurodyn Inc. announced today that it has acquired from Galantos Pharma GmbH, Mainz, Germany all assets related to their Alzheimer's prescription drug candidate - Memogain. Memogain has completed an extensive preclinical development program and is ready to proceed into Phase 1 clinical trials in late 2013. The terms of the acquisition were not disclosed.

5 Sep 2013

Perrigo Company and Teva Pharmaceutical launch generic equivalent to temozolomide

Teva Pharmaceutical Industries Ltd. and Perrigo Company today announced the launch of the generic equivalent to Temodar (temozolomide).

13 Aug 2013

Brand-name and generic drug makers take fight to states

The battle concerns state notification laws that would require pharmacists to notify doctors and patients when they substitute generic versions of drugs derived from living organisms known as biologics.

12 Aug 2013

CVS Caremark net revenues increase 1.7% in Q2 2013

CVS Caremark Corporation today announced operating results for the three months ended June 30, 2013.

6 Aug 2013

PharMerica reports net income of $10.2 million for Q2 2013

PharMerica Corporation, a national provider of pharmacy services, today reported its financial results for the second quarter and six months ended June 30, 2013.

2 Aug 2013

Teva, Lonza decide to discontinue biosimilars collaboration

Teva Pharmaceutical Industries and Lonza Group today announced that following a strategic review of the Teva-Lonza Joint Venture (TL-JV), the companies have decided to discontinue their collaboration for the development, manufacturing and marketing of biosimilars.

25 Jul 2013

Supreme Court sides with generic drug makers

The Supreme Court ruled on Monday that generic drugmakers cannot be sued under state law for adverse reactions to their products, a decision that consumer advocates called a blow to patient safety. In a 5-4 vote, the court ruled for Mutual Pharmaceutical Co, owned by Sun Pharmaceutical Industries Ltd, overturning a multimillion-dollar jury award to a badly injured patient in New Hampshire who alleged a generic drug she had taken was unsafe based on its chemical design (Hurley and Berkrot, 6/24).

26 Jun 2013

High Court: Feds can sue pharmaceutical companies over deals to delay generic drug sales

The Supreme Court ruled Monday that the Federal Trade Commission can challenge name brand drug makers for potential antitrust violations.

19 Jun 2013

First Edition: June 18, 2013

Today's headlines include reports about a new publicity push in support of the health law.

18 Jun 2013

Teva to present abstracts on AZILECT at MDS meeting

Teva Pharmaceutical Industries Ltd. announced today that a number of abstracts will be presented during the 17th Annual International Congress of Parkinson's Disease and Movement Disorders in Sydney, Australia, June 16-20, 2013, also known as the Movement Disorders Society.

15 Jun 2013

Viewpoints: Medicaid expansion 'makes sense'; Budget cuts hurt Alzheimer's research; Lack of transparency in generic Rx prices

The numbers in the Rand study ... should not be a surprise to people who have been paying attention. Numerous studies now, including in Missouri, have pointed to the simple reality of the policy implications of the ACA to argue for Medicaid expansion.

12 Jun 2013

FDA accepts Teva Pharmaceutical's sNDA for COPAXONE

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has accepted for review the company's supplemental new drug application for COPAXONE (glatiramer acetate injection) 40mg/ 1mL, a higher concentration dose of COPAXONE that offers a less frequent three times a week dosing regimen administered subcutaneously for patients with relapsing-remitting multiple sclerosis.

31 May 2013

Subsidiary of Indian drug firm pleads guilty, agrees to $500 million penalty

A subsidiary of India's largest pharmaceutical company has agreed to pay a record $500 million in fines and penalties for selling adulterated drugs and lying to federal regulators in a case that is part of an ongoing crackdown on the quality of generic drugs flowing into the U.S.

15 May 2013

First Edition: May 14, 2013

Today's headlines include reports about an Obama administration plan to delay Medicaid DSH payment reductions.

14 May 2013

Akorn reports record consolidated revenue of $73.9 million in first quarter 2013

Akorn, Inc., a niche generic pharmaceutical company, today reported financial results for its first quarter ended March 31, 2013.

7 May 2013

IGI Laboratories net revenues increase 101% to $3.7M in first quarter 2013

IGI Laboratories, Inc., a New Jersey based topical generic drug development and manufacturing company, announced its financial results for the first quarter ended March 31, 2013.

26 Apr 2013

FDA grants orphan-drug designation to XEN402 for treatment of pain associated with EM

Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc. announced today that the US Food and Drug Administration has granted orphan-drug designation to the investigational drug XEN402 being developed for the treatment of pain associated with erythromelalgia.

24 Apr 2013

BD receives FDA approval for second prefilled injectable drug

BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the U.S. Food and Drug Administration has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables.

From BD (Becton, Dickinson and Company) 24 Apr 2013